Management of Increased Anger or Irritability in Patients Taking Wellbutrin (Bupropion)
If a patient develops increased anger or irritability while taking Wellbutrin, discontinue the medication immediately and assess the patient for neuropsychiatric adverse events, as these symptoms may represent precursors to more serious behavioral changes or suicidality. 1
Immediate Assessment and Action
The FDA drug label explicitly warns that symptoms including irritability, hostility, aggressiveness, and agitation have been reported in patients taking bupropion for both depression and smoking cessation 1. These neuropsychiatric symptoms warrant immediate attention because:
- They may represent precursors to emerging suicidality or worsening depression 1
- They can occur in patients with or without pre-existing psychiatric disease 2
- Some patients may experience worsening of underlying psychiatric illness 2
Monitor specifically for:
- Severity and abruptness of symptom onset
- Whether anger/irritability was part of the patient's baseline presentation
- Concurrent emergence of anxiety, panic attacks, impulsivity, or mood changes
- Any suicidal ideation or behavior 1
Clinical Decision Algorithm
Step 1: Determine Severity
- Severe symptoms (abrupt onset, not part of baseline, accompanied by suicidal thoughts): Discontinue bupropion immediately 1
- Moderate symptoms (persistent, interfering with function): Strongly consider discontinuation
- Mild symptoms (transient, dose-related): Consider dose reduction or switching formulations
Step 2: Evaluate Contributing Factors
Check for potential exacerbating factors:
- Alcohol use: Bupropion-alcohol interaction can precipitate aggressive behavior 3. One case report documented unexpected violent outburst in a previously non-violent patient after combining bupropion with alcohol
- Dose escalation: Adverse effects including agitation are dose-related 2. Doses exceeding 450 mg/day carry increased risk 4
- Recent dose increase: Symptoms often emerge during dose adjustments 1
Step 3: Consider Formulation Issues
If therapeutic benefit was good but tolerability is problematic, switching from XL to SR formulation may be considered, as different formulations can have varying side effect profiles 5. However, this should only be attempted if symptoms are mild and after careful risk-benefit discussion.
Important Clinical Caveats
The 2016 NCCN smoking cessation guidelines note that while neuropsychiatric side effects are uncommon, providers must monitor for development or worsening of serious issues including increased hostility, depression, or suicidal behavior 6. The guidelines emphasize weighing substantial benefits of treatment versus these risks and discontinuing if signs occur.
Agitation/excitement was the most common cause for discontinuation in clinical trials, occurring in 9.1% of bupropion patients 7. This is not a rare side effect.
The 2009 Mayo Clinic guideline on tobacco dependence specifically states: "Although smoking cessation alone has been associated with increased anxiety, anger, changes in behavior, depressed mood, and increased depression, if any of these symptoms occur in a patient taking varenicline [or bupropion], treatment should be discontinued immediately and the patient should be assessed" 2.
Alternative Management Strategies
If bupropion must be discontinued due to anger/irritability:
For depression: Switch to an SSRI or SNRI, which have different adverse effect profiles 8, 9. Cognitive behavioral therapy is equally effective as second-generation antidepressants and may have fewer adverse effects 9.
For smoking cessation: Consider switching to nicotine replacement therapy or varenicline (though varenicline also carries neuropsychiatric warnings) 6, 2.
Monitoring After Discontinuation
Continue supportive care and monitoring even after discontinuation, as symptoms may persist in some cases despite stopping the medication 1. The FDA label emphasizes ongoing monitoring until symptoms resolve.
Do not restart bupropion in patients who developed significant anger, hostility, or aggressive behavior, as this represents a serious adverse reaction that is likely to recur 1.